The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together.
Learn more about the ECOG/ACRIN-EA6141 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
